Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Real-world Evidence of Diagnostic Testing and Treatment Patterns in U.S. Breast Cancer Patients with Implications for Treatment Biomarkers from RNA-sequencing Data

Louis E. Fernandes, Caroline G. Epstein, Alexandria M. Bobe, Joshua S.K. Bell, Martin C. Stumpe, Michael E. Salazar, Ameen A. Salahudeen, Ruth A. Pe Benito, Calvin McCarter, Benjamin D. Leibowitz, Matthew Kase, Catherine Igartua, Robert Huether, Ashraf Hafez, Nike Beaubier, Michael D. Axelson, Mark D. Pegram, Sarah L. Sammons, Joyce A. O’Shaughnessy, Gary A. Palmer
doi: https://doi.org/10.1101/2020.08.07.20168401
Louis E. Fernandes
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline G. Epstein
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandria M. Bobe
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua S.K. Bell
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin C. Stumpe
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael E. Salazar
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ameen A. Salahudeen
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth A. Pe Benito
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Calvin McCarter
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin D. Leibowitz
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Kase
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Igartua
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Huether
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashraf Hafez
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nike Beaubier
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Axelson
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark D. Pegram
2Stanford University School of Medicine, Stanford, CA, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah L. Sammons
3Department of Medicine, Duke University Medical Center, Duke University, Durham, NC, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce A. O’Shaughnessy
4Texas Oncology and US Oncology, Dallas, TX, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary A. Palmer
1Tempus Labs, Chicago, IL, U.S.A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gary.palmer@tempus.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

INTRODUCTION We performed a retrospective analysis of longitudinal real-world data (RWD) from breast cancer patients to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also assessed the value of transcriptome profiling as a complementary tool for determining molecular subtypes.

PATIENTS AND METHODS De-identified, longitudinal data were analyzed after abstraction from U.S. breast cancer patient records structured and stored in the Tempus database. Demographics, clinical characteristics, molecular subtype, treatment history, and survival outcomes were assessed according to strict qualitative criteria. RNA sequencing and clinical data were used to predict molecular subtypes and signaling pathway enrichment.

RESULTS The clinical abstraction cohort (n=4,000) mirrored U.S. breast cancer demographics and clinical characteristics indicating feasibility for RWE generation. Among HER2+ patients, 74.2% received anti-HER2 therapy, with ~70% starting within 3 months of a positive test result. Most non-treated patients were early stage. In this RWD set, 31.7% of patients with HER2+ IHC had discordant FISH results recorded. Among patients with multiple HER2 IHC results at diagnosis, 18.6% exhibited intra-test discordance. Through development of a whole-transcriptome model to predict IHC receptor status in the molecular sequenced cohort (n=400), molecular subtypes were resolved for all patients (n=36) with equivocal HER2 statuses from abstracted test results. Receptor-related signaling pathways were differentially enriched between clinical molecular subtypes.

CONCLUSION RWD in the Tempus database mirrors the overall U.S. breast cancer population. These results suggest real-time, RWD analyses are feasible in a large, highly heterogeneous database. Furthermore, molecular data may aid deficiencies and discrepancies observed from breast cancer RWD.

Competing Interest Statement

All authors with the exception of Mark D. Pegram, Sarah Sammons, and Joyce O'Shaughnessy are employees of Tempus Labs. Sarah Sammons receives research funding from Eli Lilly and Astra Zeneca, and serves on advisory boards for Daiichi Sankyo, Eli Lilly, Foundation Medicine, Novartis, and Sermonix. Joyce O'Shaughnessy has received honoraria from or serves on advisory boards for AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals, and Takeda. There are no other financial interests to disclose.

Funding Statement

All authors with the exception of Mark D. Pegram, Sarah Sammons, and Joyce O'Shaughnessy are employees of Tempus Labs.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was submitted to the Advarra Institutional Review Board. The IRB determined the research was exempt from IRB oversight and approved a waiver of HIPAA authorization for this study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Relevant data are available within the text, figures, tables, and supplementary information.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 11, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Real-world Evidence of Diagnostic Testing and Treatment Patterns in U.S. Breast Cancer Patients with Implications for Treatment Biomarkers from RNA-sequencing Data
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Real-world Evidence of Diagnostic Testing and Treatment Patterns in U.S. Breast Cancer Patients with Implications for Treatment Biomarkers from RNA-sequencing Data
Louis E. Fernandes, Caroline G. Epstein, Alexandria M. Bobe, Joshua S.K. Bell, Martin C. Stumpe, Michael E. Salazar, Ameen A. Salahudeen, Ruth A. Pe Benito, Calvin McCarter, Benjamin D. Leibowitz, Matthew Kase, Catherine Igartua, Robert Huether, Ashraf Hafez, Nike Beaubier, Michael D. Axelson, Mark D. Pegram, Sarah L. Sammons, Joyce A. O’Shaughnessy, Gary A. Palmer
medRxiv 2020.08.07.20168401; doi: https://doi.org/10.1101/2020.08.07.20168401
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Real-world Evidence of Diagnostic Testing and Treatment Patterns in U.S. Breast Cancer Patients with Implications for Treatment Biomarkers from RNA-sequencing Data
Louis E. Fernandes, Caroline G. Epstein, Alexandria M. Bobe, Joshua S.K. Bell, Martin C. Stumpe, Michael E. Salazar, Ameen A. Salahudeen, Ruth A. Pe Benito, Calvin McCarter, Benjamin D. Leibowitz, Matthew Kase, Catherine Igartua, Robert Huether, Ashraf Hafez, Nike Beaubier, Michael D. Axelson, Mark D. Pegram, Sarah L. Sammons, Joyce A. O’Shaughnessy, Gary A. Palmer
medRxiv 2020.08.07.20168401; doi: https://doi.org/10.1101/2020.08.07.20168401

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Informatics
Subject Areas
All Articles
  • Addiction Medicine (164)
  • Allergy and Immunology (417)
  • Anesthesia (93)
  • Cardiovascular Medicine (867)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (398)
  • Epidemiology (8597)
  • Forensic Medicine (4)
  • Gastroenterology (391)
  • Genetic and Genomic Medicine (1775)
  • Geriatric Medicine (170)
  • Health Economics (376)
  • Health Informatics (1252)
  • Health Policy (625)
  • Health Systems and Quality Improvement (472)
  • Hematology (198)
  • HIV/AIDS (380)
  • Infectious Diseases (except HIV/AIDS) (10354)
  • Intensive Care and Critical Care Medicine (554)
  • Medical Education (193)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1692)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (330)
  • Occupational and Environmental Health (451)
  • Oncology (934)
  • Ophthalmology (265)
  • Orthopedics (104)
  • Otolaryngology (172)
  • Pain Medicine (115)
  • Palliative Medicine (40)
  • Pathology (256)
  • Pediatrics (541)
  • Pharmacology and Therapeutics (257)
  • Primary Care Research (210)
  • Psychiatry and Clinical Psychology (1788)
  • Public and Global Health (3877)
  • Radiology and Imaging (629)
  • Rehabilitation Medicine and Physical Therapy (324)
  • Respiratory Medicine (525)
  • Rheumatology (208)
  • Sexual and Reproductive Health (171)
  • Sports Medicine (159)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)